234 related articles for article (PubMed ID: 32860624)
1. Lack of Drug-Drug Interaction Between Cimetidine, a Renal Transporter Inhibitor, and Imeglimin, a Novel Oral Antidiabetic Drug, in Healthy Volunteers.
Chevalier C; Perrimond-Dauchy S; Dubourg J; Fouqueray P; Bolze S
Eur J Drug Metab Pharmacokinet; 2020 Dec; 45(6):725-733. PubMed ID: 32860624
[TBL] [Abstract][Full Text] [Related]
2. In Vitro Investigation, Pharmacokinetics, and Disposition of Imeglimin, a Novel Oral Antidiabetic Drug, in Preclinical Species and Humans.
Clémence C; Fouqueray P; Sébastien B
Drug Metab Dispos; 2020 Dec; 48(12):1330-1346. PubMed ID: 33020063
[TBL] [Abstract][Full Text] [Related]
3. A drug-drug interaction study to evaluate the impact of peficitinib on OCT1- and MATE1-mediated transport of metformin in healthy volunteers.
Shibata M; Toyoshima J; Kaneko Y; Oda K; Nishimura T
Eur J Clin Pharmacol; 2020 Aug; 76(8):1135-1141. PubMed ID: 32472157
[TBL] [Abstract][Full Text] [Related]
4. Competitive inhibition of the luminal efflux by multidrug and toxin extrusions, but not basolateral uptake by organic cation transporter 2, is the likely mechanism underlying the pharmacokinetic drug-drug interactions caused by cimetidine in the kidney.
Ito S; Kusuhara H; Yokochi M; Toyoshima J; Inoue K; Yuasa H; Sugiyama Y
J Pharmacol Exp Ther; 2012 Feb; 340(2):393-403. PubMed ID: 22072731
[TBL] [Abstract][Full Text] [Related]
5. Proguanil and cycloguanil are organic cation transporter and multidrug and toxin extrusion substrates.
van der Velden M; Bilos A; van den Heuvel JJMW; Rijpma SR; Hurkmans EGE; Sauerwein RW; Russel FGM; Koenderink JB
Malar J; 2017 Oct; 16(1):422. PubMed ID: 29061131
[TBL] [Abstract][Full Text] [Related]
6. Effect of cimetidine, a model drug for inhibition of the organic cation transport (OCT2/MATE1) in the kidney, on the pharmacokinetics of glycopyrronium.
Dumitras S; Sechaud R; Drollmann A; Pal P; Vaidyanathan S; Camenisch G; Kaiser G
Int J Clin Pharmacol Ther; 2013 Oct; 51(10):771-9. PubMed ID: 24040847
[TBL] [Abstract][Full Text] [Related]
7. Mechanistic in vitro studies confirm that inhibition of the renal apical efflux transporter multidrug and toxin extrusion (MATE) 1, and not altered absorption, underlies the increased metformin exposure observed in clinical interactions with cimetidine, trimethoprim or pyrimethamine.
Elsby R; Chidlaw S; Outteridge S; Pickering S; Radcliffe A; Sullivan R; Jones H; Butler P
Pharmacol Res Perspect; 2017 Oct; 5(5):. PubMed ID: 28971610
[TBL] [Abstract][Full Text] [Related]
8. Impact of the organic cation transporter 2 inhibitor cimetidine on the single-dose pharmacokinetics of the glucosylceramide synthase inhibitor lucerastat in healthy subjects.
Boof ML; Halabi A; Ufer M; Dingemanse J
Eur J Clin Pharmacol; 2020 Mar; 76(3):431-437. PubMed ID: 31836927
[TBL] [Abstract][Full Text] [Related]
9. N(1)-methylnicotinamide as an endogenous probe for drug interactions by renal cation transporters: studies on the metformin-trimethoprim interaction.
Müller F; Pontones CA; Renner B; Mieth M; Hoier E; Auge D; Maas R; Zolk O; Fromm MF
Eur J Clin Pharmacol; 2015 Jan; 71(1):85-94. PubMed ID: 25552403
[TBL] [Abstract][Full Text] [Related]
10. The Nonmetabolized β-Blocker Nadolol Is a Substrate of OCT1, OCT2, MATE1, MATE2-K, and P-Glycoprotein, but Not of OATP1B1 and OATP1B3.
Misaka S; Knop J; Singer K; Hoier E; Keiser M; Müller F; Glaeser H; König J; Fromm MF
Mol Pharm; 2016 Feb; 13(2):512-9. PubMed ID: 26702643
[TBL] [Abstract][Full Text] [Related]
11. Contribution of MATE1 to Renal Secretion of the NMDA Receptor Antagonist Memantine.
Müller F; Weitz D; Derdau V; Sandvoss M; Mertsch K; König J; Fromm MF
Mol Pharm; 2017 Sep; 14(9):2991-2998. PubMed ID: 28708400
[TBL] [Abstract][Full Text] [Related]
12. Role of organic cation transporter OCT2 and multidrug and toxin extrusion proteins MATE1 and MATE2-K for transport and drug interactions of the antiviral lamivudine.
Müller F; König J; Hoier E; Mandery K; Fromm MF
Biochem Pharmacol; 2013 Sep; 86(6):808-15. PubMed ID: 23876341
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of Imeglimin in Subjects with Moderate Hepatic Impairment.
Chevalier C; Dubourg J; Bolze S; Fouqueray P
Clin Pharmacokinet; 2021 Apr; 60(4):485-490. PubMed ID: 33169345
[TBL] [Abstract][Full Text] [Related]
14. Importance of OCT2 and MATE1 for the Cimetidine-Metformin Interaction: Insights from Investigations of Polarized Transport in Single- And Double-Transfected MDCK Cells with a Focus on Perpetrator Disposition.
Müller F; Weitz D; Mertsch K; König J; Fromm MF
Mol Pharm; 2018 Aug; 15(8):3425-3433. PubMed ID: 29975542
[TBL] [Abstract][Full Text] [Related]
15. Fampridine is a Substrate and Inhibitor of Human OCT2, but not of Human MATE1, or MATE2K.
Xiao G; Rowbottom C; Boiselle C; Gan LS
Pharm Res; 2018 Jun; 35(8):159. PubMed ID: 29915999
[TBL] [Abstract][Full Text] [Related]
16. Elucidation of
Miyake T; Mizuno T; Takehara I; Mochizuki T; Kimura M; Matsuki S; Irie S; Watanabe N; Kato Y; Ieiri I; Maeda K; Ando O; Kusuhara H
Drug Metab Dispos; 2019 Nov; 47(11):1270-1280. PubMed ID: 31511257
[TBL] [Abstract][Full Text] [Related]
17. No Effect of Plazomicin on the Pharmacokinetics of Metformin in Healthy Subjects.
Choi T; Komirenko AS; Riddle V; Kim A; Dhuria SV
Clin Pharmacol Drug Dev; 2019 Aug; 8(6):818-826. PubMed ID: 30605260
[TBL] [Abstract][Full Text] [Related]
18. Efavirenz reduces renal excretion of lamivudine in rats by inhibiting organic cation transporters (OCT, Oct) and multidrug and toxin extrusion proteins (MATE, Mate).
Ceckova M; Reznicek J; Deutsch B; Fromm MF; Staud F
PLoS One; 2018; 13(8):e0202706. PubMed ID: 30114293
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of OCT2, MATE1 and MATE2-K as a possible mechanism of drug interaction between pazopanib and cisplatin.
Sauzay C; White-Koning M; Hennebelle I; Deluche T; Delmas C; Imbs DC; Chatelut E; Thomas F
Pharmacol Res; 2016 Aug; 110():89-95. PubMed ID: 27178732
[TBL] [Abstract][Full Text] [Related]
20. Organic cation transporter and multidrug and toxin extrusion 1 co-mediated interaction between metformin and berberine.
Shi R; Xu Z; Xu X; Jin J; Zhao Y; Wang T; Li Y; Ma Y
Eur J Pharm Sci; 2019 Jan; 127():282-290. PubMed ID: 30428337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
